[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350073-105":59,"doc-detail-350073-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-gpa33-with-car-macrophages-a-novel-immunotherapeutic-approach-for-colorectal-cancer","Targeting GPA33 with CAR-macrophages - a novel immunotherapeutic approach for colorectal cancer","","The study investigates GPA33-targeted CAR-macrophages as a novel adoptive cell immunotherapy for colorectal cancer, addressing limited efficacy of immune checkpoint inhibitors for most CRC patients. GPA33 is a surface antigen expressed in nearly all colorectal cancers, making it a promising therapeutic target. Single B cell isolation and single-cell PCR were used to generate an scFv for GPA33 CAR. Engineered CAR-Ms showed antigen-dependent M1-like polarization, enhanced tumor phagocytosis, and increased proinflammatory cytokine secretion, with in vivo xenograft studies demonstrating tumor growth inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-gpa33-with-car-macrophages-a-novel-immunotherapeutic-approach-for-colorectal-cancer/350073/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-gpa33-with-car-macrophages-a-novel-immunotherapeutic-approach-for-colorectal-cancer/350073.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why target GPA33 in colorectal cancer immunotherapy?","Question",{"text":112,"@type":113},"GPA33 is a surface antigen expressed in nearly all colorectal cancers. Targeting it provides a promising direction for immunotherapy in CRC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were GPA33 CAR-macrophages (CAR-Ms) generated and validated?",{"text":117,"@type":113},"The study cloned antibody variable regions to build the GPA33 CAR scFv, then generated CAR-Ms by lentiviral transfection and PMA induction. Targeted phagocytosis, polarization, cytokine secretion, and tumoricidal effects were assessed using fluorescence microscopy, flow cytometry, ELISA, and in vitro/in vivo anti-tumor assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings on CAR-Ms’ anti-tumor effects?",{"text":121,"@type":113},"CAR-Ms mediated antigen-dependent M1-like polarization, increasing tumor phagocytic activity and proinflammatory cytokine secretion. In vivo xenograft experiments showed that CAR-M injection inhibited colon cancer tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350073,1791005709,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Wang et al. Journal of Translational Medicine (2026) 24:459  \n[https://doi.org/10.1186/s12967-026-07897-6](https://doi.org/10.1186/s12967-026-07897-6)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nTargeting GPA33 with CAR-macrophages: a novel immunotherapeutic approach for colorectal cancer  \nDaijun Wang1, Wenzhang Wu1, Luxi Yang1,2,3, Caihao Qu1, Yujie Wei1, Yang Zhao1,2,3,5* and Yumin Li 1,3,4*  \nAbstract  \nBackground In recent years, tumor immunotherapy, exemplified by immune checkpoint inhibitors, has achieved remarkable success in certain patients. However, the efficacy of such therapies remains minimal in the majority of colorectal cancer patients. Overcoming the suppression of the tumor immune microenvironment and developing novel immunotherapeutic strategies have become focal points of research in this field. Adoptive cell therapy demonstrates immense potential, with chimeric antigen receptor macrophages exhibiting inherent advantages in combating solid tumors. GPA33, a surface antigen that is expressed in nearly all colorectal cancers, is a promising target for immunotherapy in colorectal cancer. This study aims to evaluate the potential therapeutic effects of GPA33-targeted CAR-macrophages in colorectal cancer.  \nMethods Using single B cell isolation technology and single-cell PCR technology, we cloned the complete variable region sequences of mouse antibody light and heavy chains, which were subsequently employed to construct the scFv fragment of GPA33 CAR. CAR-Ms were generated by transfectingTHP-1 cells with lentivirus, followed by PMA induction. The targeted phagocytic activity of CAR-Ms was observed using fluorescence microscopy, and their targeted phagocytosis, polarization trends, and tumoricidal effects were validated through flow cytometry. Cytokine secretion was quantified using ELISA assays. The in vitro and in vivo anti-tumor effects of CAR-Ms were assessed through bioluminescence measurements, while the safety of CAR-Ms was evaluated using HE staining and a small animal biochemical analyzer.  \nResults Based on the successful development of a novel GPA33 antibody with high affinity and specificity, we constructed CAR-Ms targeting GPA33 . For the in vitro experiments, GPA33-specific CAR-Ms were able to mediate antigen-dependent M1-like polarization of macrophages, enhancing their tumor phagocytic activity and proinflammatory cytokine secretion. In in vivo experiments, a xenograft model of colon cancer was established using immunodeficient mice, and the injection of CAR-Ms effectively inhibited tumor growth.  \n*Correspondence:  \nYang Zhao [ery_zhaoyang@lzu.edu.cn](ery_zhaoyang@lzu.edu.cn)[ ](ery_zhaoyang@lzu.edu.cn)Yumin Li  \n[liym@lzu.edu.cn](liym@lzu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nWang et al. Journal of Translationa","cbCaipH9mp4dr1DU","https://ap.wps.com/l/cbCaipH9mp4dr1DU","pdf",11217962,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Introduction","[{\"question\":\"Why target GPA33 in colorectal cancer immunotherapy?\",\"answer\":\"GPA33 is a surface antigen expressed in nearly all colorectal cancers. Targeting it provides a promising direction for immunotherapy in CRC.\"},{\"question\":\"How were GPA33 CAR-macrophages (CAR-Ms) generated and validated?\",\"answer\":\"The study cloned antibody variable regions to build the GPA33 CAR scFv, then generated CAR-Ms by lentiviral transfection and PMA induction. Targeted phagocytosis, polarization, cytokine secretion, and tumoricidal effects were assessed using fluorescence microscopy, flow cytometry, ELISA, and in vitro/in vivo anti-tumor assays.\"},{\"question\":\"What were the main findings on CAR-Ms’ anti-tumor effects?\",\"answer\":\"CAR-Ms mediated antigen-dependent M1-like polarization, increasing tumor phagocytic activity and proinflammatory cytokine secretion. In vivo xenograft experiments showed that CAR-M injection inhibited colon cancer tumor growth.\"}]","Targeting GPA33 with CAR-macrophages - a novel immunotherapeutic approach for colorectal cancer | PDF",1790087024,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e7516ccd9e9ececc19940c2ecec6e35.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59fe6d060c93cb0452551cbe3fca6e2a.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80ac1699e90ae501086ba54b80e8c0b9.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fe7829be923bdde9bfc4d6d4b1446c0.webp",980,1306]